EXOC7

Across TCGA pan-cancer cohorts, EXOC7 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated EXOC7 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher EXOC7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EXOC7 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.

OV, LUSC, and ESCA are the cancer types where EXOC7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.289	0.845	<.001	48	view →
LUSC	DFS	Median	All	0.191	0.646	.011	18	view →
ESCA	DFS	Median	II,III,IV	0.208	0.528	.016	12	view →
UCS	DFS	Median	All	0.126	0.523	.009	6	view →
PAAD	OS	Median	All	0.131	0.640	.012	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	6	view →
HNSC	OS	Median	II,III,IV	0.222	0.710	.031	6	view →
SARC	DFS	Median	All	0.137	0.594	.009	3	view →
COAD	DFS	Median	All	1.000	0.775	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

EXOC7–OV (OS)

Open the OV breakdown →